Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1

Phase 1 Study of ADX-626 in Healthy Participants

NCT07081503 · tracked via the Priya Life Science UK tracker
Phase
Phase 1
Started
2025-08-12
Last updated
2026-09-10

Condition(s) studied

Healthy Adult Participants

Investigational drug(s) / intervention(s)

ADX-626Placebo

ADX-626: siRNA duplex oligonucleotide

Placebo: Saline

Study summary

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Key Inclusion Criteria: * Age 18 to 45 years at the time of informed consent * Males or women of non-childbearing potential (WONCBP) * Willing to comply with all study requirements while participating * Suitable venous access for blood sampling. * Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg/m2 * Normal laboratory results including liver enzymes, hemoglobin, platelet count, and coagulation parameters * Willing to use acceptable contraception methods if applicable Key Exclusion Criteria: * Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer * History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders. * Current infection * Participation in an interventional drug study within the last 90 days

Primary outcome measure(s)

  • Safety of ADX-626 in Healthy Participants — Day 1 to Day 365
    Incidence, relationship and severity of adverse events and serious adverse events

Trial sites (1)

FacilityCityRegionStatus
Richmond Pharmacology London United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07081503 on ClinicalTrials.gov ↗ ← All trials in the UK